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Ethical implications of the use of whole genome
methods in medical research
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The use of genome-wide association studies (GWAS) in medical research and the increased ability to share data give a new twist
to some of the perennial ethical issues associated with genomic research. GWAS create particular challenges because they
produce ﬁne, detailed, genotype information at high resolution, and the results of more focused studies can potentially be used
to determine genetic variation for a wide range of conditions and traits. The information from a GWA scan is derived from DNA
that is a powerful personal identiﬁer, and can provide information not just on the individual, but also on the individual’s
relatives, related groups, and populations. Furthermore, it creates large amounts of individual-speciﬁc digital information that is
easy to share across international borders. This paper provides an overview of some of the key ethical issues around GWAS:
consent, feedback of results, privacy, and the governance of research. Many of the questions that lie ahead of us in terms of the
next generation sequencing methods will have been foreshadowed by GWAS and the debates around ethical and policy issues
that these have created.
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Genome-wide association studies (GWAS) seek to establish associa-
tions between genomic variants and diseases or quantitative traits.1,2
The methodology involves the genotyping of a large number of
genomic variants – presently usually just over 1 million variants per
individual – for a large number of individuals with and without the
disease of interest, or for those who show variance on the trait(s) in
question. To identify these small genetic contributions, such studies
usually involve at least a thousand individuals, and usually many
more. Advances in the quality and efﬁciency of sequencing methods,
such as the next generation sequencing techniques, will assist GWAS
and generate vast quantities of rich data on many thousands of
individuals.3,4 With the cost of whole genome sequencing technologies
falling rapidly, it is anticipated that whole genome sequences will
no longer be the result of large scientiﬁc endeavours such as the
Human Genome Project, but will be routinely used in GWAS and
other studies.
The use of GWAS in medical research and the increased ability to
share data give a new twist to the perennial issues of consent, feedback
of results, privacy, and the governance of research, as many commen-
tators have discussed.5–8 GWAS create particular challenges because
they produce ﬁne, detailed, genotype information at high resolution,
and the results of more focused studies can potentially be used to
determine genetic variation for a wide range of conditions and traits.
Although samples and data will have personal identiﬁers removed,
individuals may still be re-identiﬁable because of the richness of the
data derived from the analysis. The information from a GWA scan is
derived from DNA that is a powerful personal identiﬁer, and can
provide information not just on the individual, but also on the
individual’s relatives, related groups, and populations. Furthermore,
it creates large amounts of individual-speciﬁc digital information that
is easy to share across international borders. The data produced are
often shared informally, but more formal mechanisms have
been put in place by funders to ensure the rapid sharing of GWAS
data, such as the requirements to deposit data sets in open access
archives. Examples are the European Genotype Archive and dbGaP
(NIH-USA).
Many of the ethical challenges of GWAS arise from the quantity and
signiﬁcance of the data generated, and these issues will be heightened
by the new sequencing techniques under development. Hence, many
of the questions that lie ahead of us will have been foreshadowed by
GWAS and the debates around ethical and policy issues that these have
created. It is appropriate, therefore, to revisit some of the ethical issues
in contemporary genomic studies and examine how they have arisen,
and how they might best be addressed. This paper focuses on four key
areas of particular signiﬁcance for the use of whole genome techniques
in medical research: consent; feedback of incidental ﬁndings; privacy;
and the governance of research.
THE CONTEXT OF GENOMIC RESEARCH
There are three important aspects of the context of whole genome
research methods that may inﬂuence the ethical challenges that they
raise. First, these methods are being used alongside the increasing
accumulation of samples and information, which are held by projects,
large international consortia, or within biobanks. Such resources can
then be used for a number of different research projects as the
information is compared, used, and exchanged between researchers
who come together to address speciﬁc research questions. These data
and sample storage infrastructures meet the scientiﬁc need for very
large sample sizes to understand the complexity of genotypic, pheno-
typic, and environmental interactions. Funders in collaboration with
the scientiﬁc community have been instrumental in facilitating and
supporting such trends, with the creation of genomic reference
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and more recently, the 1000 Genomes project, with the purpose of
increasing scientiﬁc advances.
Second, data sharing is becoming a crucial element of scientiﬁc
policy with the development of more open access guidelines. Funders
are encouraging researchers to deposit data created in newly-funded
projects to be shared with others, and increasingly the presumption is
that the data should be shared.9,10 Funders have also been active in
ﬁnancing and supporting the establishment of data-generating pro-
jects, especially for the creation of sequence data using GWAS
methods. Examples of such projects are the Wellcome Trust Case
Control Consortium (WTCCC) and MalariaGEN in the United
Kingdom and the Genetic Association Information Network (GAIN)
in the United States. The data created by these projects can be a
valuable resource for potentially many different research projects and
purposes. This raises a number of ethical issues as many of the
principles and procedures in medical research are not designed for
wide-scale data sharing.
Third, these genomic methods are used in a social context
where privacy concerns about the loss and unauthorized use of
digital information have come to take a prominent place, and
where the democratization of biological technologies means that
individuals have greater access to their own genomes through
direct-to-consumer genetic testing companies as well as genealogical
registries and ancestry tracing companies. These events outside of
medical research cannot be ignored, as there is the potential for
these to have an effect on the medical research context, which in the
case of an unfavourable event could undermine the public trust and
support that is necessary for medical research to continue and to
thrive. The ethical challenges raised by the use of whole genome
sequencing methods and data sharing, such as consent, need
to be considered in the light of these events occurring in the broader
social context.
Consent
The notion that informed consent is needed from participants in
research has been a sine qua non of research ethics since the
mid-twentieth century. This conception of consent, along with the
concomitant power to withdraw from research without prejudice,
arose originally in the context of biomedical research. It had the aim of
protecting participants from abuse and from potential physical harms,
and focused on clinical interventions and on the collection of samples
rather than on data collection per se. In its inception, informed
consent was strongly concerned with the protection of individuals.
Genomics research, however, moves away from these origins on
several counts.
In genomics research, potential medical and physical harms are less
relevant than potential harms of infringements of privacy and the
misuse of information. It is questionable how informed consent,
traditionally conceived, can accommodate these concerns, which are
of course heightened as research techniques produce ever more
detailed information, and as more and more genomic data are shared.
The complexity of genomics research, together with the difﬁculty of
providing precise speciﬁcations of future use of data, have also
prompted serious concerns about whether any consent to such
research can be adequately ‘informed’. Furthermore, although the
traditional notion of informed consent focuses on the individual, in
genomics research there are pressing issues also for the family,
community, and population groups.
Recent attempts to suggest solutions to these problems reveal
substantial disagreements over both fundamental conceptual issues
and practical details. There is disagreement over the place of informed
consent as a central norm in genomics research ethics and whether a
broad consent is more appropriate for the collection of samples and
information that will involve many future research projects. It has also
been suggested that informed consent should carry less ethical weight
and that alternative values should take a more central role. For
instance, some have argued that veracity could become a key value
in truthfully explaining the limitations of withdrawal and of con-
ﬁdentiality to participants.8 A more common approach has been to
retain the values that underpin informed consent, such as autonomy
and self-determination, but to use other mechanisms to give voice to
them. Suggestions are to supplement informed consent with govern-
ance structures, often with participant representation;7 and to enable
individuals to have greater say about the use of their information
through information technology. Such mechanisms would also pro-
vide an audit trail to ensure the proper use of data derived from a
GWAS.
Existing samples and genomic data are seen as valuable resources
for GWAS, especially given the need for large sample sizes, but there is
no consensus about their reuse or the issue of re-consent. This again
raises the question of how central a role the informed consent of
individuals is to whole genome research. There are those who argue
that risks to individuals are limited and of a different nature to the
risks of clinical research, and that the furtherance of medical science is
a valuable goal that takes precedence. Likewise, the ethical basis for any
continued guarantee of the possibility of withdrawal of consent is in
dispute. It could be grounded on protection from harms, or on
autonomous control over personal data. Different practical implica-
tions arise from these different grounds. There is disagreement over
the extent that there can be complete withdrawal, and how this might
be done, as this can potentially be difﬁcult and costly when data sets
are shared.
Finally, the implications of participation in genomics research
extend beyond an understanding of consent grounded in individual
rights. Many have suggested encouraging discussions on research
participation with family members. Resolving this point, however,
necessitates grappling with the difﬁcult conﬂuence of more indivi-
dualistic and more communitarian approaches to ethics. There is the
danger that suggestions to involve the family will be nothing more
than gestures at this major problem; on the other hand, a perhaps
graver danger is that these vague admonitions will overlook the
delicate and often charged complexity that makes up families, and
that harms may result. There is a pressing need to learn from insights
gained elsewhere, such as in genetic counselling and in family studies.
Likewise, calls to involve the community in consent pose large ethical
issues about individual and group rights, which may be different for
communities across the globe.
Feedback of ﬁndings
Feedback of ﬁndings may be considered to be an important part of
building and maintaining public trust in research. Providing partici-
pants with information about the general ﬁndings of research, such as
publications based on the research, is an uncontroversial and welcome
practice. In contrast, the feedback of individual results remains
controversial in many areas of research11 and particularly in the area
of whole genome sequencing. Areas of research where relative agree-
ment has been reached include research involving MRI and CTscans,
as well as communicable diseases.12 In these settings, the nature of the
technology and the science involved means that researchers are
sometimes faced with ﬁndings of clear, veriﬁable clinical signiﬁcance
for research participants. In the context of genetic studies, there
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condition, researchers or research teams have a moral obligation to
feed this information back to research participants.12,13 In cases where
ﬁndings are of a less serious nature, untreatable, or of uncertain
signiﬁcance, the potential beneﬁts for participants of being informed
need to be balanced against the participant’s right not to know. The
thoughtful handling of such issues is of clear relevance to the
maintenance of public trust in the research process.14
Feeding back research results from genomics studies is
complicated by a number of factors.11,15,16 The most signiﬁcant is
that GWA is a research tool and is not designed for clinical diagnosis.
Therefore, the results from GWA studies are applicable only in
exceptional cases of clear clinical utility for research participants,
and the techniques used in a research setting are generally not of
the standard that would be required for clinical validation.1 Many of
the discoveries of whole genome methods identify genetic variants that
are responsible for very small increases in disease risk. It is quite
common for putative associations not to be replicated in subsequent
research. Even for valid associations, the signiﬁcance for individuals
can be very hard to interpret, especially for complex disorders where
very many genetic variants, epigenetic effects, and environmental
factors all have a part in disease genesis. In time, this currently
uncertain information may also be shown to be of clinical relevance,
raising the possible question of future contact of participants for
feedback. However, even now, the ﬁne detail results obtained from
GWAS can provide information on a number of conditions, which
can lead to the possibility of incidental ﬁndings of known variants that
are clinically valid.15
In such situations, there is a need for management pathways14 to
determine whether or what information is fed back; who is responsible
for feeding back results; and whether this also extends to other family
members. Genomics is a highly complex ﬁeld, bringing together
experts from different disciplines, and extremely high levels of
expertise would be needed to interpret ﬁndings at the cutting edge
of genomic science. Feeding back raw data without any clinical
interpretation may be not only of limited use but also greatly
misleading. However, good research practice would suggest that
policies and procedures should be put in place to decide whether
and how to feedback clinically valid results or incidental ﬁndings
should these eventualities occur. Currently, these management path-
ways do not exist for all studies. This raises a number of questions.
The ﬁrst is the scope of the obligation to feedback and whether it
includes the individual research participants as well as their
families.11,15 The second question is whether the obligation applies
just to the researchers who conducted the original study or extends to
secondary researchers who obtain the data through data sharing.11,15
The third issue is how this should be done and what mechanisms need
to be put into place to ensure that this happens in a way that is
responsible and proportionate.
Finally, as with other ethical issues we have discussed, the changing
landscape in which GWAS research takes place is likely to affect the
question of feedback of ﬁndings. In particular, the introduction of
consumer genetics services may change the expectations of partici-
pants in research. For example, 23andWe (23andMe’s research arm)
conducts research using the genetic and phenotypic information of
individuals who have paid to use their service. Will participants in
GWAS thus come to expect feedback of similar types of information to
those provided by consumer genetics ﬁrms? The implications for the
research relationship will be profound if there is a shift from
participants as ‘health information altruists’17 to participants who
have similar expectations to ‘customers’.
Privacy of research participants
Privacy and conﬁdentiality have traditionally been the cornerstones of
ethical medical research practice.18 Informed consent has been one
way of protecting privacy by allowing individuals to choose whether
they undertake the privacy risks associated with particular types of
research. Although the clinical application of GWAS is still largely
unknown, some of the potential privacy risks identiﬁed in genetics are
the diagnosis of a disease or disclosure of paternity information that
then becomes known to others, such as other family members,
insurers, or employers. The protection of conﬁdentiality in medical
research has been maintained by safeguarding the identiﬁability of
research participants by de-identifying data, and by keeping their
records and personal information secure. Standard privacy measures
have been the removal of identiﬁers and coding to de-identify data;
placing ﬁrewalls between those who hold the coding keys and
researchers; as well as restrictions on access to research data and the
requirement of research ethics approval.
Research on existing samples or data that are anonymized or de-
identiﬁed is seen as posing little risk to individual privacy, and in
many cases could proceed without additional informed consent.19
However, the ﬁne, detailed, uniquely identiﬁable genomic information
that is produced by GWAS technologies, as well as the increase in data
sharing, presents signiﬁcant challenges to these traditional mechan-
isms of protecting privacy and conﬁdentiality.
Individual sequence data can be used for many different research
uses, as the same variants on the genome can be implicated in the
expression of many different phenotypes. Once data have been
generated by GWAS, it is of interest to many researchers and can be
used for many research purposes on many conditions. At the time a
sample is collected, it may be possible to inform individuals of the
initial research use, but it is very difﬁcult to provide individuals with
all the necessary information about the secondary research uses of the
data and all the researchers who will have access to the summary or
raw data that are generated by GWAS, so as to enable them to make an
informed decision about whether they are willing to accept the
possible privacy risks of genomics research. Informed consent for
every secondary research use is very difﬁcult to achieve unless there is
ongoing contact with research participants. A practical solution has
been the use of broad consent, which is consent to a broad range of
research uses, coupled with approval by a research ethics committee.
This is controversial as it undermines the fundamental principle of
medical research and the right to privacy, whereby individuals should
have the knowledge in advance and be able to choose how their
personal information is used.20
Efforts to protect privacy by de-identifying the data produced by
GWAS are also problematic, as the traditional dichotomy between
identiﬁable and non-identiﬁable data is hard to ensure.21 What is non-
identiﬁable at present may not remain so with increased knowledge of
the genome and more sophisticated analytical and statistical techni-
ques. Genomics is moving very fast. Even 2 years ago, the state of the
art was such that identifying individuals from genomic data was
difﬁcult, expensive, and time-consuming.5 However, in 2008, Homer
et al22 showed a method of identifying individuals within a pooled
sample from reference samples. Sharing of research data and techno-
logical advances will increase the possibility of re-identiﬁcation of
individuals. In addition, biological, mathematical, and statistical
techniques are likely to continue to be developed to make identiﬁca-
tion easier in the future from smaller samples of DNA sequence.
Identiﬁcation is also possible not just within a single database, but
by linking together multiple sources of information, whether genomic,
medical or social, so that it is possible to infer (or reveal) an
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are being created through the linkage of existing data sets or through
new biomedical resources and biobanks. To carry out research,
comparisons are routinely being made between web-based genomic
reference libraries and the GWAS results held by researchers. Increa-
singly, the research data are being shared through informal means or
deposition in archives or resources that are accessible by many
researchers. The possibility of being able to directly identify indivi-
duals as well as infer an individual, family, or group identity becomes
easier as the data become richer and more detailed through the linkage
of different data sets. Recent research has shown that it is possible to
triangulate data sources freely available to the research community to
identify individuals believed to be anonymous.23
At the same time that detailed data sets are accumulating within the
research community, cheaper sequencing techniques have enabled
commercial companies to make genomic information available to
the public over the internet. Consumers can now have access to
commercial genotyping of their genome from direct-to-consumer
testing companies. Some companies encourage individual subscribers
to share their information with other family members and friends.
Linking these sources to other information that is readily available on
the internet, such as births, deaths, and marriage records held by
government bodies, provides the means to make information that was
previously thought to be non-identifying, potentially identiﬁable.
These companies make whole genome information available to the
general public and it will no longer be held exclusively in the hands of
scientists. Researchers are bound by research governance require-
ments, professional codes of conduct, and obligations of conﬁdenti-
ality, but many who gain access to genomic information as it becomes
more freely available will not necessarily be under similar obligations.
At the moment, the identiﬁcation of an individual in a collection of
samples may not disclose very much clinically relevant information
about that individual. However, it is important to consider the
implication of the disclosure not only on the basis of current knowl-
edge, but also for the future. With a better understanding of the
genome, sequence information may reveal more about an individual’s
risk of disease.24 Technical methods can be used to protect the privacy
of individuals, such as limiting the proportion of the genome released,
statistically degrading the data, and reversibly de-identifying through
codes.5 However, as was shown by Homer’s paper, what is reasonably
believed to be anonymous at one point in time may not remain so in
the future. Many commentators argue that absolute promises of
privacy and conﬁdentiality are simply not possible in the context of
genomics research.5,8,22 Protecting the privacy of research participants
has long been regarded as essential to maintain public trust in medical
research. Making promises that cannot be honoured has the potential
to undermine much of the goodwill that the public has in relation to
medical research. A loss of public trust will have a detrimental effect
on research recruitment and could have many long-term effects.
Governance of research
Medical research is largely governed at the national level through a
number of checks and balances that are based on professional norms
embedded in practice. These are in turn supported and strengthened
by a range of national guidelines and institutional requirements that
are enacted by key gatekeepers such as research ethics committees and
to some extent, funders. Some countries have governance frameworks
for research that are complex, contradictory, and confusing, with a
number of different bodies asserting speciﬁc requirements and guide-
lines. These systems are severely tested in the case of global genomic
research that involves data sharing and whole genomes. It is difﬁcult
for research ethics committees to exercise their mandate to oversee
research and to protect the interests of research participants when
their authority is nationally based and the assessment of the risks of
such research involves specialist expertise. For many GWAS data-
generating projects, special governance systems have been established
to supplement current oversight systems.
Research ethics committees were established within institutions for
individual research projects, rather than to assess modern multicentre
projects, such as GWAS, that span international borders. These
projects create similar problems for national research ethics frame-
works around the world. Many research ethics committees do not
have the appropriate expertise and knowledge to deal with the
complex legal and ethical issues that GWAS activities raise, and neither
do they have the appropriate authority. Research ethics committees
have traditionally held the principal investigators accountable for the
execution of ethical research. In the case of data sharing of GWAS
summary data and ﬁne detailed phenotypic data, it is virtually
impossible to hold the original collector responsible for the research
or activities of researchers, as they may not know who may be located
outside of the jurisdiction and the research ethics committee control.
It is therefore difﬁcult for committees to continue adequate monitor-
ing of research and data the generation of which they originally
approved.9 The fact that governance structures and legal frameworks
are nationally based also fails to address the reality of increasing global
research activity in the ﬁeld of genomics and the way in which the
science is developing.
Research ethics committees have focused mainly on protecting
research participants’ interests and so in assessing genomics research
tend to focus on the consent process25 and on approving the reuse of
samples.26 Such committees are already facing increasing challenges in
reviewing complex research proposals, particularly in relation to
proportionality assessment (risks, beneﬁts, safeguards) informed con-
sent, and privacy protection.27 The use of the GWAS technology
further raises particular privacy and feedback issues that are often
beyond the scope of the expertise of many research ethics committees.
It is therefore not clear how already over-burdened committees could
take on the role of monitoring and approving data access – a task that
requires signiﬁcant insight into the techniques used to produce and
analyse data in genomics. Neither are they equipped to carry out
privacy risk assessments of global data sharing.
As the mechanisms for establishing precedents in research ethics
committee decision-making are informal, there can be also be con-
siderable variation in the decisions of committees. It is in the area of
emerging technologies and innovative, global, collaborative research
proposals that there can be the most discrepancies in decision-making
between ethics committees. Decisions and procedures may vary within
regions in countries, but the differences are most acute between
countries, and where differing, ethical and legal frameworks exist.
This creates additional burdens for collaborative, international con-
sortia that have to obtain research ethics approval in each country for
different parts of the research project. Further, if samples and
information are being collected in different jurisdictions of the
consortium to address a particular research question, they may be
subject to different research ethics decisions.
To combat some of these ethical concerns, special Data Access
Committees (DACs) have been established in the data-generating
projects, such as the WTCCC and GAIN, to supervise access to
these GWAS data sets. DACs determine who should have access to
data and on what grounds. This primarily involves establishing
whether a scientist is a ‘bona ﬁde researcher’. The criteria used for
this assessment are still in the process of being developed and are
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be obtained from a research ethics committee as DAC approval is
simply for access to the data set. However, there is no one body that is
looking at disclosure when all of the genomic data sets are analysed
together and there is a possibility of identiﬁcation by using material
available on the web.9
The difﬁculty with the governance of GWAS through current
oversight structures is that it is largely carried out at the national
level, on a case by case basis, by bodies that have inadequate
enforcement powers and whose focus does not address the incre-
asingly complex implications of this kind of genomics research. The
issue for new methodologies such as whole genome sequencing
methods is that it takes some time before a critical amount of expertise
is built up within the research ethics community to make approval for
research projects an efﬁcient and straightforward process. In the case
of emerging technologies, this can result in frustration for researchers
and a slowing down of the research process. Data sharing between
large international projects, or researchers based in different jurisdic-
tions, can also lead to multiple applications for the same research to
different nationally-based bodies with different requirements.9
CONCLUSION
We are at an important time in terms of policy making and thinking
about the future of genomics research. The technologies in relation to
individual whole genome sequencing are developing quickly and at
the same time there is increased data sharing between researchers,
which is encouraged by funders and made possible because of
the internet and e-science grid technology. This poses challenges for
the traditional focus of research ethics on individuals, as concerns are
widened out from the participant to family and population groups,
and as responsibilities are widened from individual researchers in close
contact with research recruits to large, often global, research networks
that may store data and samples for indeﬁnite periods into the future.
The use of whole genome methods gives a new twist to perennial
ethical issues, such as consent, feedback, and the protection of privacy,
and the governance of research. The fact that it is very difﬁcult to
obtain informed consent for all new research uses well into the future
and that it is impossible to ensure the complete privacy of participants
challenges some of the fundamental ethical principles of medical
research. The potential threats to privacy, conﬁdentiality, and asso-
ciated informational harms created by global data sharing present
somewhat different ethical questions to the physical risks that are
centrally at issue within the sphere of clinical research ethics. We need
to rethink the current reliance on anonymization and consent as
sufﬁcient safeguards to protect participant interests in research,
particularly in the case of infrastructure that aim to link existing
research archives and repositories of information. It is impossible to
obtain the traditional standard of informed consent for every
secondary research use unless there is ongoing contact with research
participants. The mechanisms that must be developed to protect
individual autonomy must be carefully thought through. This may
require a reevaluation of the fundamental tenets of the participant,
research, and society relationship and the basis on which this should
rest for genomic research.
Importantly, too, the signiﬁcance of these ethical challenges is
shaped by the changing landscape outside of genomics research, a
landscape that includes widespread concerns about the use of personal
information, as well as the activities of private and commercial entities
and not just academic and research institutions. The commercializa-
tion of genome sequences and the way that this is being made rapidly
available to the public has an impact on the way that people think
about genomic research conducted in academic and research institu-
tions. In light of the technological advances in sequencing methods
and greater data sharing, the following key areas need further con-
sideration:
  Alternative mechanisms to informed consent to allow individuals
to exercise their autonomy;
  Feedback and the development of feedback management pathways;
  The development of governance mechanisms for research suitable
for global data sharing.
These are difﬁcult issues that need further thought and analysis to ensure
the ongoing participation of participants in research and public trust.
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